FR15C0047I1 - - Google Patents

Info

Publication number
FR15C0047I1
FR15C0047I1 FR15C0047C FR15C0047I1 FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1 FR 15C0047 C FR15C0047 C FR 15C0047C FR 15C0047 I1 FR15C0047 I1 FR 15C0047I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0047(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0047I1 publication Critical patent/FR15C0047I1/fr
Application granted granted Critical
Publication of FR15C0047I2 publication Critical patent/FR15C0047I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR15C0047C 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine Active FR15C0047I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (fr) 2002-04-16 2003-04-14 Antagonistes tricycliques du recepteur de thrombine

Publications (2)

Publication Number Publication Date
FR15C0047I1 true FR15C0047I1 (fr) 2015-08-28
FR15C0047I2 FR15C0047I2 (fr) 2016-05-06

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0047C Active FR15C0047I2 (fr) 2002-04-16 2015-07-03 Antagonistes tricycliques du recepteur de thrombine

Country Status (34)

Country Link
US (3) US7304078B2 (fr)
EP (5) EP1860106B1 (fr)
JP (2) JP4558331B2 (fr)
KR (1) KR101026929B1 (fr)
CN (1) CN1659162B (fr)
AR (1) AR039570A1 (fr)
AT (3) ATE378330T1 (fr)
AU (1) AU2003221932B2 (fr)
BR (1) BRPI0309309B8 (fr)
CA (1) CA2482858C (fr)
CY (3) CY1107184T1 (fr)
DE (3) DE60331114D1 (fr)
DK (2) DK2065384T3 (fr)
EC (1) ECSP045368A (fr)
ES (3) ES2357876T3 (fr)
FR (1) FR15C0047I2 (fr)
HK (3) HK1070887A1 (fr)
IL (1) IL164585A (fr)
LT (1) LTC1495018I2 (fr)
LU (1) LU92759I2 (fr)
MX (1) MXPA04010308A (fr)
MY (1) MY144040A (fr)
NL (1) NL300746I2 (fr)
NO (2) NO330500B1 (fr)
NZ (2) NZ575139A (fr)
PE (1) PE20040412A1 (fr)
PL (1) PL214718B1 (fr)
PT (2) PT2065384E (fr)
RU (2) RU2329264C9 (fr)
SG (1) SG164279A1 (fr)
SI (2) SI1495018T1 (fr)
TW (1) TWI343919B (fr)
WO (1) WO2003089428A1 (fr)
ZA (1) ZA200408342B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
ATE406366T1 (de) * 2004-05-28 2008-09-15 Schering Corp Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
CA2582353A1 (fr) * 2004-10-06 2006-04-20 University Of Rochester Traitement de l'hypertension pulmonaire au moyen d'un agent inhibant une voie du facteur tissulaire
PL2206697T3 (pl) * 2005-01-14 2012-03-30 Merck Sharp & Dohme Egzo- oraz diastereoselektywna synteza analogów himbacyny
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
US7772276B2 (en) * 2005-01-14 2010-08-10 Schering Corporation Exo-selective synthesis of himbacine analogs
CN101137614A (zh) * 2005-01-14 2008-03-05 先灵公司 喜巴辛类似物的手性炔丙醇和酯中间体的制备
WO2006076564A1 (fr) * 2005-01-14 2006-07-20 Schering Corporation Synthese des analogues de l'himbacine
KR20070116066A (ko) * 2005-03-31 2007-12-06 쉐링 코포레이션 스피로사이클릭 트롬빈 수용체 길항제
WO2007075808A2 (fr) * 2005-12-20 2007-07-05 Schering Corporation Procedes de prevention et/ou de traitement d’un trouble de proliferation de cellules
EP1971336A2 (fr) * 2005-12-22 2008-09-24 Shering Corporation Antagonistes de recepteur de thrombine en tant que phophylaxie aux complications de derivation cardiopulmonaire
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2266976B1 (fr) 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Antagonistes de récepteur de thrombine à cycle condensé
AR061664A1 (es) * 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008060372A2 (fr) * 2006-10-04 2008-05-22 Schering Corporation Antagonistes du récepteur de la thrombine basés sur l'unité tricyclique modifiée de l'himbacine
US8153664B2 (en) 2006-10-04 2012-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
WO2008079260A2 (fr) * 2006-12-22 2008-07-03 Schering Corporation Promoteurs de désintégration dans des formulations de forme solide obtenues par un procédé de granulation par voie humide
JP2010522169A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション トロンビン受容体アンタゴニストの使用による、経皮的インターベンション後の有害事象の低減
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
AU2009211888B2 (en) 2008-02-05 2013-06-20 Sanofi Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (fr) * 2008-04-02 2009-10-08 Schering Corporation Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4)
EP2300435A2 (fr) 2008-05-19 2011-03-30 Schering Corporation Composés hétérocycliques en tant qu`inhibiteurs du facteur ixa
WO2010141525A1 (fr) * 2009-06-04 2010-12-09 Schering Corporation Métabolite actif d'un antagoniste des récepteurs de la thrombine
EP2440191A2 (fr) 2009-06-08 2012-04-18 Schering Corporation Antagoniste du récepteur de la thrombine et comprimé de clopidogrel à dose fixe
WO2011017296A1 (fr) 2009-08-04 2011-02-10 Schering Corporation Dérivés de pyrimidine 4,5,6-trisubstituée comme inhibiteurs du facteur ixa
WO2011128421A1 (fr) 2010-04-16 2011-10-20 Sanofi Pyridyl-vinyl-pyrroles tricycliques utilisés comme inhibiteurs du par1
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
EP3024550A4 (fr) * 2013-07-22 2016-12-07 Merck Sharp & Dohme Co-cristal de l'antagoniste du récepteur par-1 de vorapaxar et aspirine
EP3035928B1 (fr) * 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC Dérivés bicycliques de 3'-pyridyl substitué-6,6-difluoro himbacine
WO2015026693A1 (fr) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Dérivés bicycliques de 7a-amide substitué-6,6-difluoro himbacine
EP3035930A4 (fr) * 2013-08-22 2017-03-08 Merck Sharp & Dohme Corp. Dérivés bicycliques de 7a-hétérocycle substitué-6,6-difluoro himbacine
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (fr) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. Nouvelle composition pharmaceutique à base de vorapaxar et de métoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
CN107304200B (zh) * 2016-04-22 2021-09-21 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
JP2023534704A (ja) 2020-07-22 2023-08-10 ヤンセン ファーマシューティカ エヌ．ベー． 第ｘｉａ因子阻害剤として有用な化合物
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
PE133799A1 (es) * 1997-11-25 2000-01-10 Schering Corp Antagonistas del receptor de trombina
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
CA2410177C (fr) 2000-06-15 2010-05-11 Schering Corporation Antagonistes du recepteur de la thrombine
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
MXPA04003610A (es) 2001-10-18 2004-07-27 Schering Corp Analogos de himbacina como antagonistas del receptor de trombina.

Also Published As

Publication number Publication date
KR101026929B1 (ko) 2011-04-04
EP1982984B1 (fr) 2013-02-13
PE20040412A1 (es) 2004-07-12
LU92759I2 (en) 2015-08-31
HK1123302A1 (en) 2009-06-12
NO330500B1 (no) 2011-05-02
DK2065384T3 (da) 2011-05-02
AU2003221932A1 (en) 2003-11-03
DE60317493T2 (de) 2008-09-18
ES2297150T3 (es) 2008-05-01
SI1495018T1 (sl) 2008-04-30
JP4558331B2 (ja) 2010-10-06
RU2004133375A (ru) 2005-07-10
US20070179187A1 (en) 2007-08-02
EP1982984A2 (fr) 2008-10-22
JP2005528406A (ja) 2005-09-22
EP1495018B1 (fr) 2007-11-14
CY1111363T1 (el) 2015-08-05
ZA200408342B (en) 2006-05-31
AU2003221932B2 (en) 2007-11-22
EP1982984A3 (fr) 2008-10-29
NO20044963L (no) 2004-11-15
JP2010132710A (ja) 2010-06-17
CY1107184T1 (el) 2012-10-24
EP2062890B1 (fr) 2011-01-05
BRPI0309309B8 (pt) 2021-05-25
DE60331114D1 (de) 2010-03-11
DK1495018T3 (da) 2008-02-18
HK1070887A1 (en) 2005-06-30
MY144040A (en) 2011-07-29
CA2482858A1 (fr) 2003-10-30
ATE378330T1 (de) 2007-11-15
NO2015016I1 (no) 2015-07-20
MXPA04010308A (es) 2005-02-03
BRPI0309309B1 (pt) 2018-09-04
RU2329264C9 (ru) 2009-04-20
PL373332A1 (en) 2005-08-22
PL214718B1 (pl) 2013-09-30
DE60335679D1 (de) 2011-02-17
US7304078B2 (en) 2007-12-04
ES2357876T3 (es) 2011-05-03
AR039570A1 (es) 2005-02-23
EP1860106A1 (fr) 2007-11-28
CY2015029I2 (el) 2016-04-13
EP2065384B1 (fr) 2011-01-05
PT1495018E (pt) 2008-02-19
CA2482858C (fr) 2010-11-30
EP2062890A1 (fr) 2009-05-27
SG164279A1 (en) 2010-09-29
NL300746I1 (fr) 2016-01-21
BR0309309A (pt) 2005-02-15
NL300746I2 (fr) 2016-01-21
HK1129893A1 (en) 2009-12-11
CN1659162B (zh) 2011-08-31
WO2003089428A1 (fr) 2003-10-30
FR15C0047I2 (fr) 2016-05-06
KR20040099441A (ko) 2004-11-26
CY2015029I1 (el) 2016-04-13
IL164585A (en) 2010-11-30
SI2065384T1 (sl) 2011-05-31
TWI343919B (en) 2011-06-21
ATE455774T1 (de) 2010-02-15
DE60317493T3 (de) 2018-07-12
NZ575139A (en) 2010-08-27
IL164585A0 (en) 2005-12-18
US20070270439A1 (en) 2007-11-22
RU2329264C2 (ru) 2008-07-20
ATE494284T1 (de) 2011-01-15
LTC1495018I2 (lt) 2017-04-10
US7713999B2 (en) 2010-05-11
DE60317493D1 (en) 2011-01-13
RU2008106401A (ru) 2009-08-27
ES2338171T3 (es) 2010-05-04
NO2015016I2 (no) 2015-07-09
EP1495018A1 (fr) 2005-01-12
ES2297150T7 (es) 2012-03-16
EP1860106B1 (fr) 2010-01-20
US20030216437A1 (en) 2003-11-20
TW200404068A (en) 2004-03-16
EP1495018B3 (fr) 2011-03-16
CN1659162A (zh) 2005-08-24
EP2065384A1 (fr) 2009-06-03
ECSP045368A (es) 2005-01-03
PT2065384E (pt) 2011-03-16
NZ535880A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
BE2019C547I2 (fr)
BE2019C510I2 (fr)
BE2018C021I2 (fr)
BE2017C049I2 (fr)
BE2017C005I2 (fr)
BE2016C069I2 (fr)
BE2016C040I2 (fr)
BE2016C013I2 (fr)
BE2018C018I2 (fr)
BE2016C002I2 (fr)
BE2015C078I2 (fr)
FR15C0047I1 (fr)
BE2015C017I2 (fr)
BE2014C053I2 (fr)
BE2014C051I2 (fr)
BE2014C041I2 (fr)
BE2014C030I2 (fr)
BE2014C016I2 (fr)
BE2014C015I2 (fr)
BE2013C063I2 (fr)
BE2013C039I2 (fr)
BE2011C038I2 (fr)
JP2003188402A5 (fr)
JP2003190159A5 (fr)
JP2003182329A5 (fr)